ANI Pharmaceuticals CEO Nikhil Lalwani's 2021 pay jumps 76% to $6.5M
ANI Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: March 25, 2022
ANI Pharmaceuticals reported fiscal year 2021 executive compensation information on March 25, 2022.
In 2021, five executives at ANI Pharmaceuticals received on average a compensation package of $2.9M, a 33% increase compared to previous year.
Average pay of disclosed executives at ANI Pharmaceuticals
Nikhil Lalwani, Chief Executive Officer, received $6.5M in total, which increased by 76% compared to 2020. 67% of Lalwani's compensation, or $4.4M, was in stock awards. Lalwani also received $1.4M in bonus, $715K in salary, as well as $15K in other compensation.
For fiscal year 2021, the median employee pay was $50,403 at ANI Pharmaceuticals. Therefore, the ratio of Nikhil Lalwani's pay to the median employee pay was 130 to one.
Stephen P. Carey, Chief Financial Officer, received a compensation package of $2.9M, which increased by 3% compared to previous year. 61% of the compensation package, or $1.7M, was in stock awards.
James G. Marken, Senior Vice President, Operations and Product Development, earned $1.7M in 2021, a 7% decrease compared to previous year.
Christopher K. Mutz, Head of Rare Disease, received $1.6M in 2021.
Ori Gutwerg, Senior Vice President, Generics, earned $1.5M in 2021.
Related executives
Nikhil Lalwani
ANI Pharmaceuticals
Chief Executive Officer
Stephen Carey
ANI Pharmaceuticals
Chief Financial Officer
James Marken
ANI Pharmaceuticals
Senior Vice President, Operations and Product Development
Ori Gutwerg
ANI Pharmaceuticals
Senior Vice President, Generics
Christopher Mutz
ANI Pharmaceuticals
Head of Rare Disease
You may also like
Source: SEC filing on March 25, 2022.